NEW YORK, March 6, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/scyx.
The investigation concerns whether SCYNEXIS and certain of its officers and/or directors have issued materially misleading business information to the investing public.
On March 2, 2017, after-market hours, Scynexis revealed that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on clinical trials for the intravenous formulation of its lead product candidate SCY-078, "until the FDA completes a review of all available pre-clinical and clinical data." Scynexis encouraged investors that "[t]he clinical hold decision was issued by the FDA following a review of three mild-to-moderate thrombotic events in healthy volunteers receiving the IV formulation of SCY-078 at the highest doses and highest concentrations in a Phase 1 study." Following this news, Scynexis stock dropped as much as $0.67 per share, or 20.49%, during intraday trading on March 3, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of SCYNEXIS, you can assist this investigation by visiting the firm's site: www.bgandg.com/scyx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-scynexis-inc-scyx-300418282.html
SOURCE Bronstein, Gewirtz & Grossman, LLC